Rainbow Children's Medicare Limited has executed definitive transaction documents, including a Shareholders' Agreement, for the proposed development of a new children's and women's hospital at Malad, Mumbai. The project will be undertaken through its wholly owned subsidiary, Rainbow Women & Children's Hospital Private Limited (RWCHPL), and carries an estimated project cost of approximately ₹90 Crore. The transaction was disclosed to stock exchanges on July 29, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Strategic Capacity Addition in Western India

The proposed hospital at Malad, Mumbai is designed to add an incremental capacity of 100 beds, expanding Rainbow Children's Medicare's healthcare delivery network in Maharashtra. The company currently operates with an existing capacity of 2,435 beds and a capacity utilisation of 46.3%. The new facility is expected to be commissioned by Q1 FY27-28, subject to receipt of necessary approvals and completion of construction and development activities. The project will be financed entirely through internal accruals, with Rainbow Children's Medicare contributing approximately ₹68,40,00,000 of the total estimated project cost.

The following table summarises the key parameters of the proposed capacity addition:

Induction of Fountainhead TCHM Healthcare LLP

As part of the transaction, Fountainhead TCHM Healthcare LLP (LLP) is proposed to be inducted as an equity investor in RWCHPL. The LLP is promoted by a group of doctors — Dr. Susan Veena Fernandes, Dr. Vinay Hanamesh Joshi, and Dr. Allan Mark Pereira. Pursuant to the transaction documents, the LLP is proposed to acquire a 24% equity stake in RWCHPL, with the consideration for the equity transfer set at ₹24,000. The transaction is expected to be completed on or before August 31, 2026.

Upon completion, RWCHPL will cease to be a wholly owned subsidiary of Rainbow Children's Medicare and will continue as a subsidiary, with the following post-transaction shareholding structure:

Rainbow Children's Medicare will retain 76% of the equity share capital of RWCHPL and will continue to exercise control over the subsidiary. The buyer does not belong to the promoter, promoter group, or group companies of Rainbow Children's Medicare, and the proposed investment is to be made on an arm's length basis.

RWCHPL: Target Entity Background

Rainbow Women & Children's Hospital Private Limited was incorporated on December 13, 2010, and is engaged in managing and running hospitals, dispensaries, maternity homes, health centres, clinics, and diagnostic centres for providing medical services, surgery, and other allied services. The entity operates in India and is classified under the Healthcare Services industry. Its authorised capital stands at ₹50,00,000 and paid-up capital at ₹1,00,000. The turnover history of RWCHPL for the past three financial years is as follows:

Expanding the Maharashtra Healthcare Network

The 100-bed brownfield hospital in Malad, Mumbai complements a previously announced 150-bed regional hub in Pune, which is expected to commence operations in FY29. Together, these two facilities are intended to establish a hub-and-spoke network across Maharashtra, expanding Rainbow Children's Medicare's presence in Western India. The company's existing footprint spans multiple cities including Bengaluru, Chennai, Delhi, Guwahati, Hyderabad, Rajahmundry, Vijayawada, Visakhapatnam, and Warangal. The Malad project is aimed at enhancing the company's ability to deliver specialised paediatric, women's, and neonatal care across Maharashtra.

Rainbow Childrens Medicare Limited shareholders approved a ₹3.5 per equity share dividend for FY26 and ratified the re-appointment of key board members during its 28th Annual General Meeting held on July 29, 2026. The virtual meeting, conducted via Video Conference/Other Audio-Visual Means (VC/OAVM) in compliance with the Companies Act, 2013 and SEBI Listing Regulations, saw high participation with 90,558 shareholders on the record date. The declaration underscores continued profitability, while the voting results reveal nuanced shareholder sentiment regarding specific director appointments.

The meeting commenced at 10:00 A.M. (IST) and concluded with the unblocking of votes at 11:20 A.M. Remote e-voting was facilitated by National Securities Depository Limited (NSDL) from July 25, 2026, to July 28, 2026. M/s. KVSS & CO. LLP, represented by CS K.V.S. Subramanyam, served as the scrutinizer. The statutory auditors, M/s. S.R. Batliboi & Associates LLP, confirmed an unqualified audit report for FY26, supporting the financial integrity of the dividend declaration.

Voting Results and Resolutions

Shareholders overwhelmingly supported the adoption of audited standalone and consolidated financial statements for FY26 (Resolution 1), with 99.9999% of votes cast in favor. Similarly, the dividend declaration (Resolution 2) received 99.9999% support, reflecting strong confidence in the company’s cash distribution strategy. The remuneration payable to cost auditors M/s. Lavanya and Associates LLP for FY27 (Resolution 4) was also approved with 99.9998% support.

Board Re-appointments and Mixed Sentiment

The re-appointment of Dr. Adarsh Kancharla as a Non-Executive Director (Resolution 3) received 68.23% support, with 31.77% votes against, indicating notable dissent among public institutional shareholders. In contrast, Dr. Ramesh Kancharla’s re-appointment as Chairman and Managing Director (Resolution 5) secured 99.90% support, while his remuneration package (Resolution 6) passed with 99.99% approval. Dr. Dinesh Kumar Chirla’s re-appointment as Whole-time Director (Resolution 7) and his remuneration (Resolution 8) also garnered near-unanimous support above 99.99%.

Independent director re-appointments faced moderate opposition. Mr. Santanu Mukherjee’s re-appointment (Resolution 9) received 97.14% support, with 2.86% against. Ms. Sundari R. Pisupati’s re-appointment (Resolution 10) saw similar results, with 97.11% in favor and 2.89% against. These dissenting votes primarily originated from public institutional shareholders, suggesting selective scrutiny of independent board composition.

What the Numbers Show

The near-unanimous approval of the dividend and financial statements highlights strong alignment between management and shareholders on core financial outcomes. However, the significant dissent against Dr. Adarsh Kancharla’s re-appointment and the moderate opposition to independent directors suggest growing shareholder activism regarding board governance and independence. This divergence implies that while operational performance is widely accepted, investors are increasingly exercising their voting rights to influence board structure and oversight mechanisms.